-
Mashup Score: 18Dupilumab treatment for atopic dermatitis linked to cutaneous T-cell lymphoma development - 28 day(s) ago
A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.“Dupilumab, a human monoclonal antibody targeting [interleukin]-4 alpha receptor, is used for the treatment of moderate to severe [AD],” Iraj Hasan, BA, a student at the West Virginia University School of Medicine, and colleagues wrote.
Source: www.healio.comCategories: General Medicine News, Allergy-ImmunologyTweet
#Dupilumab therapy for #atopic #dermatitis may be associated with the development of cutaneous T-cell #lymphoma. Stay informed about potential risks. #SkinHealth #TreatmentSafety https://t.co/Nro8SxKIjo https://t.co/NY382D5G9q